Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ophthalmic-focused Alimera goes public, nets $68.4mm

Executive Summary

A year after withdrawing its IPO, which was first filed in July 2008, Alimera Sciences Inc. (back-of-the-eye disorders) has finally gone public. It netted $68.4mm by selling 6.6mm shares at $11, and the company's venture backers bought 1.8mm of that stock. Earlier in April 2010, Alimera had hoped to issue 6mm shares for $15-17.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies